Driehaus Capital Management LLC Sells 115,614 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Driehaus Capital Management LLC reduced its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 5.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,875,876 shares of the company's stock after selling 115,614 shares during the period. Driehaus Capital Management LLC owned 2.37% of Viridian Therapeutics worth $35,961,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Voya Investment Management LLC grew its stake in Viridian Therapeutics by 5.1% in the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock worth $410,000 after acquiring an additional 1,038 shares during the period. Tudor Investment Corp ET AL increased its stake in Viridian Therapeutics by 3.0% in the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock valued at $735,000 after purchasing an additional 1,106 shares during the last quarter. R Squared Ltd purchased a new position in shares of Viridian Therapeutics during the 4th quarter worth about $26,000. Summit Investment Advisors Inc. boosted its holdings in shares of Viridian Therapeutics by 24.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after purchasing an additional 1,516 shares during the last quarter. Finally, AlphaQuest LLC increased its stake in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after acquiring an additional 1,519 shares during the last quarter.

Viridian Therapeutics Trading Up 5.9%

NASDAQ VRDN traded up $0.73 on Monday, reaching $13.12. The company had a trading volume of 942,955 shares, compared to its average volume of 1,196,147. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The stock's 50 day moving average is $13.71 and its 200-day moving average is $17.44. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -3.04 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm's revenue for the quarter was up .0% compared to the same quarter last year. Equities analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on VRDN. Needham & Company LLC cut their price target on Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. JMP Securities lowered their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. The Goldman Sachs Group lowered their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Royal Bank of Canada decreased their price target on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Viridian Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $36.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.